Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX4I5A)

Drug Name
ISIS 19218 Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
TTD Drug ID
DMX4I5A

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting CD40 messenger RNA (CD40 mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NJA-730 DM4I02O Graft-versus-host disease 4B24 Phase 1 [2]
ISIS 19213 DMD1JVZ Discovery agent N.A. Investigative [1]
ISIS 19211 DMKFCD5 Discovery agent N.A. Investigative [1]
ISIS 19220 DMIKEXD Discovery agent N.A. Investigative [1]
ISIS 19219 DMFAWGX Discovery agent N.A. Investigative [1]
ISIS 19221 DMKOFNX Discovery agent N.A. Investigative [1]
ISIS 19217 DMQK0AL Discovery agent N.A. Investigative [1]
ISIS 19212 DMLQT5F Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CD40 messenger RNA (CD40 mRNA) TT1ERKL TNR5_HUMAN Not Available [1]

References

1 US patent application no. 6,197,584, Antisense modulation of CD40 expression.
2 Clinical pipeline report, company report or official report of NapaJen Pharma.